The promising synergy of I-DXd with PD-1 inhibition, suggested by enhanced CD8 + T cell recruitment and tumor suppression, alongside a comprehensive modulation of the TME, underscores the potential of ICAM1-targeted therapy to significantly advance cervical cancer treatment. This evidence concerns the gene CD8A and cervical cancer.